Feature | August 20, 2012

Baylor Heart Hospital First in the World to Merge Two High-Tech Systems for AFib Therapy

Merging to result in reduced procedure time and higher likelihood of favorable outcome

August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.

The procedure combined the use of multi-electrode mapping (MEM) software with the Epoch platform, making the full-service cardiovascular hospital the first in the world to do so. Introduced by Biosense Webster, the software allows the physician maneuvering a MEM-enabled catheter to acquire multiple mapping points simultaneously with a higher level of detail. The Epoch platform is an advanced computer-controlled technology that allows physicians to navigate within the patient's heart with robotic precision.

Merging these two technologies means higher levels of efficiencies in mapping and correcting the patient’s cardiac arrhythmias. J. Brian DeVille, M.D., FACC, FHRS, medical director of electrophysiology and an electrophysiologist on the medical staff of the Baylor Heart Hospital, said this first-in-the-world procedure is an important step to further advancing patient care in the arena of cardiac electrophysiology.

“The integration of these two technologies confirms the Heart Hospital Baylor Plano’s commitment to excellence in patient care and providing advanced treatment to our patients,” DeVille said. “Our goal is always to seek ways to further minimize risk to the patient, which then increases the probability of favorable outcomes.”

Mark Valentine, the hospital’s president, added, “The Heart Hospital is fully committed to improving patient outcomes and that involves implementing advanced technologies that will help us fulfill that goal. We consistently strive to be on the forefront when it comes to innovation because we know that ultimately that is what will serve our patients’ interests in positive ways and help us continue to provide safe, quality, compassionate care.”

For more information: www.thehearthospitalbaylor.com

Related Content

News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation| November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab| October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Videos | EP Mapping and Imaging Systems| October 24, 2017
This video, provided by Acutus Medical, demonstrates a patient case showing the use of the AcQMap high-resolution ele
Acutus Medical Receives FDA Clearance for AcQMap Cardiac Mapping Technology
Technology | EP Mapping and Imaging Systems| October 24, 2017
Acutus Medical announced that the U.S. Food and Drug Administration (FDA) has cleared the AcQMap High Resolution...
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation| October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
Overlay Init